FEATURED

Guidelines: Assessing Industry Influence on Recommendations

Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.

CP-CML: Continue Taking Generic Imatinib?

In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic imatinib at a higher frequency compared with those given brand-name products.

Opinion: The FDA’s Take on Cannabidiol

In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.

ASCO GU 2019 Symposium

Our complete coverage of the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA.

Predictions in Medicine 2019: What's Ahead

A new partner in the fight to cure cancer. A once-unlikely source for combatting clinician burnout. These are some of the advances we and other experts predict will affect oncologists and their patients in 2019 and beyond. Take a look inside our crystal ball.

Ask the Experts: NSCLC

Cancer Therapy Advisor asked 2 experts to weigh in on recommended treatment modalities for patients with non-small cell lung cancer.

Ask the Experts: STS Clinical Insights

Cancer Therapy Advisor asked 2 experts to weigh in on the latest clinical insights into soft tissue sarcoma.

Ask the Experts: Waldenström Macroglobulinemia

Cancer Therapy Advisor asked 3 experts to weigh in on recommended treatment modalities for patients with Waldenström macroglobulinemia.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Latest Features

Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations

Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations

Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.

Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib

Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib

In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic imatinib at a higher frequency compared with those given brand-name products.

Opinion: Understanding the FDA's Take on Cannabidiol

Opinion: Understanding the FDA's Take on Cannabidiol

In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.

Immunotherapy in Glioblastoma: Peaks and Pits

Immunotherapy in Glioblastoma: Peaks and Pits

New studies in glioblastoma highlight how PD-1 inhibitors could simultaneously prompt an immune response and steer the selection of tumor clones that evade immune recognition.

Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer

Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer

At 23 years of follow-up, the cumulative incidence of death was higher among patients in the watchful waiting group compared with those in the radical prostatectomy group.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs